Evelo Biosciences

22 articles about Evelo Biosciences

• Evelo Biosciences Announces Inducement Award Plan for Expanding Leadership Team

  6/3/2021

  Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that given accelerating growth to later-stage development and the anticipated hiring and expansion of the Leadership Team, the Evelo Board of Directors has approved an inducement equity plan.

• Evelo Biosciences to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020

  7/23/2020

  Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced that it will host a conference call and live webcast at 8:30 a.m.

• 

  BioSpace Movers & Shakers, April 17

  4/17/2020

  Pharma and life sciences companies boost their executive ranks and boards with this week's Movers & Shakers.
• 

  BioSpace Movers & Shakers, Dec. 6

  12/6/2019

  Pharma and biotech companies strengthen their leadership teams and boards with this week's hires.
• 

  Clinical Catch-Up: November 4-8

  11/11/2019

  It was a busy week for clinical trial updates for the first week of November. Here’s a look.
• 

  BioSpace Movers & Shakers, Sept. 20

  9/20/2019

  Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments.
• 

  Clinical Catch-up for August 5-9

  8/12/2019

  Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.

• Evelo Biosciences Expands Executive Leadership Team

  2/8/2018

  Evelo Biosciences today announced the expansion of its executive leadership team with the appointment of Duncan McHale, M.D., Ph.D. as CMO and Michael Garcia-Webb, Ph.D. as head of people and operational excellence.

• Evelo Biosciences Announces Issuance of U.S. Patent Supporting Monoclonal Microbial Oncology Trials

  1/9/2018

  Evelo announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,855,302 covering Bifidobacteria for the treatment of cancer in combination with checkpoint inhibitors.

• Backed by Google, Evelo Bags $50 Million and Names Some Industry Vets to the Team

  7/12/2017

• Evelo To Present At BioCentury NewsMakers Conference

  9/6/2016

• Evelo And Mayo Clinic Establish Research Collaboration For Immuno-Microbiome Cancer Therapies

  8/3/2016

• Evelo And Mayo Clinic Establish Research Collaboration For Immuno-Microbiome Cancer Therapies

  8/2/2016

• Evelo and Epiva Merge to Become a Leading Immuno-Microbiome Platform Company

  7/12/2016

• Evelo Participates In White House Office Of Science And Technology Policy's National Microbiome Initiative Event

  5/13/2016

• Evelo Announces Participation At Guggenheim Microbiome Day

  4/14/2016

• University of Chicago And Evelo Sign Licensing Deal For Microbiome-Based Cancer Immunotherapy

  4/7/2016

• Evelo Establishes Scientific Advisory Board

  3/29/2016

• Evelo Establishes Core Executive Team

  1/11/2016

• Evelo Expands To New HQ In Cambridge

  12/17/2015